c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper-Reference-Cited by-同舟云学术

c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper

Published:2021-12-18 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Aurich Beate¹^ORCID,Apele‐Freimane Dina²^ORCID,Banaschewski Tobias³^ORCID,Chouchana Laurent⁴^ORCID,Day Simon⁵,Kaguelidou Florentia⁶,Kelly Lauren E.⁷^ORCID,Kindblom Jenny M.⁸^ORCID,Neubert Antje⁹^ORCID,Wong Ian C. K.¹⁰¹¹

Affiliation:

1. Department of Pharmacology Saint‐Louis Hospital Paris France

2. Neonatal Intensive Care, Women and Child Health Clinic Pauls Stradins Clinical University Hospital Riga Latvia

3. Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim University of Heidelberg Mannheim Germany

4. Regional Center of Pharmacovigilance, Department of Pharmacology Cochin Hospital, APHP, Centre, Université de Paris Paris France

5. Clinical Trials Consulting and Training Limited North Marston UK

6. Department of Pediatric Pharmacology and Pharmacogenetics, APHP, Robert Debré Hospital; Center of Clinical Investigations, INSERM CIC1426 Université de Paris Paris France

7. Department of Paediatrics and Child Health, Max Rady College of Medicine University of Manitoba Winnipeg Canada

8. Paediatric Clinical Research Center, Queen Silvia Children's Hospital Sahlgrenska University Hospital Gothenburg Sweden

9. Department of Paediatrics and Adolescent Medicine University Hospital Erlangen, Friedrich‐Alexander University Erlangen‐Nürnberg (FAU) Erlangen Germany

10. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine The University of Hong Kong China

11. Research Department of Practice and Policy, School of Pharmacy UCL London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15119

Reference145 articles.

1. World Health Organisation.Pharmacovigilance.2018.https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. Accessed August 11 2020.

2. Council for International Organizations of Medical Sciences.Practical aspects of signal detection in pharmacovigilance – Report of CIOMS Working group VIII. Geneva 2010.https://cioms.ch/working_groups/working-group-viii/. Accessed August 28 2020.

3. European Medicines Agency. Guidelines on Good Pharmacovigilance Practices (GVP)—Introductory Cover Note Last Updated with Chapter P.III on Pharmacovigilance for the Use of Medicines by Pregnant and Breastfeeding Women. 2019.https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-chapter-piii_en.pdf. Accessed August 17 2020.

4. European Medicines Agency The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Guide on Methodological Standards in Pharmacoepidemiology (Revision 8) EMA/95098/2010 Rev.8 2010.http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf. Accessed August 3 2020.

5. Drug toxicity and adverse drug reactions in children—a brief historical review;Choonara I;Paediatr Perinatal Drug Ther,2002

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should secondary pharmacogenomic variants be actively screened and reported when diagnostic genome-wide sequencing is performed in a child?;Genetics in Medicine;2024-02

2. Standardizing Paediatric Clinical Data: The Development of the conect4children (c4c) Cross Cutting Paediatric Data Dictionary;Journal of the Society for Clinical Data Management;2023-02-13

3. Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature;Therapeutic Advances in Drug Safety;2023-01

4. Quo vadis (where are you going) pharmacovigilance?;British Journal of Clinical Pharmacology;2022-11-17

5. Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports;Pediatric Drugs;2022-11-12